drug development

Novartis shares plunge after two Phase 3 trials fail

Novartis endured one of its worst weeks in recent memory after two major late-stage clinical trials failed in rapid succession, sending its shares tumbling and rattling partners and competitors across the biotech industry.

Novartis muscle disease drug fails, capping third trial setback in a week

Novartis disclosed Tuesday that its experimental drug del-desiran failed to outperform placebo in a pivotal study for the rare muscle-wasting disease myotonic dystrophy type 1, marking the company's third clinical trial setback in roughly a week.

Human-safe drug repairs DNA damage in Alzheimer’s mouse model

Neuroscientists at King's College London have found that a drug already shown to be safe in humans can reduce multiple features of Alzheimer's disease in mice by repairing broken DNA in neurons and reducing brain inflammation, according to a study…